The American pharmaceutical group Pfizer has agreed to buy rival Medivation, specialized in the production of pharmaceuticals for the treatment of cancer, for about 14 billion dollars (about 120 billion) .
Pfizer has offered shareholders Medivations 81:50 dollars per share, representing a premium of 21 percent compared with Medivation share’s closing price on Friday.
also, other competitors, such as Sanofi and Merck & amp; Co., according to Reuters sources have also expressed interest in the purchase of Medivation, based in the United States.
![Like](http://cache.addthiscdn.com/icons/v1/thumbs/facebook.gif)
![Tweet](http://cache.addthiscdn.com/icons/v1/thumbs/twitter.gif)
No comments:
Post a Comment